18 Jul 2024 • A novel vonoprazan-based triple therapy has emerged as a potent contender against the standard quadruple therapy in treating H.pylori infection.

• In 600 treatment-naive patients, researchers found that the new regimen, comprising vonoprazan 20 mg, amoxicillin 750 mg, and bismuth 220 mg, achieved an impressive per-protocol eradication rate of ≥90%.
• Remarkably, this novel treatment also boasted fewer adverse events, particularly significantly reducing bitter mouth complaints compared to the traditional therapy (3.7% vs. 16.2%, P < 0.001).

Source:JGH| Read full story